We are live on ! Find out more
OFM

Omega Fund Management Portfolio holdings

AUM $163M
1-Year Est. Return 107.06%
This Fund
S&P 500
This Quarter Est. Return
-27.79%
1 Year Est. Return
+107.06%
3 Year Est. Return
+111.75%
5 Year Est. Return
+84.24%
10 Year Est. Return
+495.59%
AUM
$489M
AUM Growth
-$219M
Cap. Flow
+$13.5M
Cap. Flow %
2.77%
Top 10 Hldgs %
88.13%
Holding
23
New
1
Increased
–
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$19.8M

Top Sells

Rank Stock Value
1
IVVD icon
Invivyd
IVVD
+$4.59M
2
REPL icon
Replimune Group
REPL
+$1.7M

Sector Composition

Rank Sector Weight
1 Healthcare 98.99%
2 Financials 1.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVB icon
1
Nuvation Bio
NUVB
$2.24B
$121M 24.71%
22,957,340
– –
REPL icon
2
Replimune Group
REPL
$814M
$79.4M 16.24%
4,673,380
-90,000
-2% -$1.7M
IMGO
3
DELISTED
Imago BioSciences, Inc. Common stock
IMGO
$58.2M 11.91%
3,018,737
– –
MORF
4
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$48.2M 9.86%
1,200,014
– –
KRON
5
DELISTED
Kronos Bio
KRON
$27.6M 5.65%
3,818,283
– –
GOSS icon
6
Gossamer Bio
GOSS
$66.5M
$27.5M 5.62%
3,164,835
– –
IMUX icon
7
Immunic
IMUX
$182M
$20.2M 4.14%
178,816
– –
ALPN
8
DELISTED
Alpine Immune Sciences Inc
ALPN
$18.2M 3.73%
2,029,580
– –
CINC
9
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$16.9M 3.47%
+966,176
New +$19.8M
IMA
10
ImageneBio Inc
IMA
$63.1M
$13.7M 2.81%
187,427
– –
ARQT icon
11
Arcutis Biotherapeutics
ARQT
$3.42B
$12M 2.46%
623,836
– –
THRX
12
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$8.2M 1.68%
711,479
– –
SANA icon
13
Sana Biotechnology
SANA
$885M
$6.97M 1.43%
843,750
– –
PRTK
14
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$5.86M 1.2%
1,971,241
– –
OMEG
15
DELISTED
Omega Alpha SPAC Class A Ordinary Shares
OMEG
$4.92M 1.01%
501,000
– –
SPRB
16
Spruce Biosciences
SPRB
$119M
$4.34M 0.89%
28,814
– –
CMPI
17
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
$4.26M 0.87%
1,335,050
– –
ICVX
18
DELISTED
Icosavax, Inc. Common Stock
ICVX
$3M 0.61%
426,395
– –
SYRS
19
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$2.99M 0.61%
251,271
– –
EPIX
20
DELISTED
ESSA Pharma
EPIX
$2.03M 0.42%
328,196
– –
JNCE
21
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$1.87M 0.38%
275,513
– –
IMCR icon
22
Immunocore
IMCR
$1.78B
$1.54M 0.32%
51,535
– –
IVVD icon
23
Invivyd
IVVD
$180M
– –
-632,855
Closed -$4.59M

Similar funds

HCCM
Hudson Canyon Capital Management New York $163M AUM 33.71% 1-Year Est. Return
PBO
Peoples Bank (Ohio) Marietta, Ohio $163M AUM 18.72% 1-Year Est. Return
PCR
Potrero Capital Research San Francisco, California $163M AUM 79.07% 1-Year Est. Return
BCM
Basso Capital Management Stamford, Connecticut $163M AUM 21.95% 1-Year Est. Return
IVGAI
Index Venture Growth Associates IV St. Helier, Jersey $163M AUM 54.88% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
TCGDR
TB Capital Gestao de Recursos Rio De Janeiro $163M AUM 20.86% 1-Year Est. Return
IPWA
International Private Wealth Advisors San Diego, California $163M AUM 16.99% 1-Year Est. Return

Omega Fund Management's Q1 2022 Portfolio in Review

As of Q1 2022, Omega Fund Management held 23 positions worth $489M, down 31% from $707M the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Omega Fund Management's Q1 2022 filing shows 1 new, 1 reduced and 1 closed positions. Its largest new stake was CinCor Pharma, Inc. Common Stock: 966,176 shares worth $16.9M. The largest sale was Invivyd, an estimated $4.59M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials.

  • Omega Fund Management's largest Q1 2022 buy was CinCor Pharma, Inc. Common Stock: 966,176 shares worth $16.9M.
  • Omega Fund Management's biggest Q1 2022 reduction was Replimune Group, cutting an estimated $1.7M.
  • Omega Fund Management fully exited Invivyd in Q1 2022, selling an estimated $4.59M.
  • Omega Fund Management's ten largest holdings make up 88% of its $489M portfolio in Q1 2022.
  • Omega Fund Management opened 1 new position and closed 1 in Q1 2022.
  • Omega Fund Management's portfolio value fell 31% quarter-over-quarter to $489M.

Based on Omega Fund Management's 13F filing for Q1 2022, filed 13 May 2022.